Sarepta Therapeutics (NASDAQ:SRPT) Raised to Hold at Zacks Research

Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

A number of other equities analysts have also issued reports on SRPT. Piper Sandler reduced their target price on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research note on Thursday, July 9th. HC Wainwright reiterated a “buy” rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 28th. Wolfe Research raised Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a report on Thursday, July 9th. Weiss Ratings lowered Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Nine equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and five have assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $25.06.

Sarepta Therapeutics Trading Up 0.2%

NASDAQ:SRPT opened at $18.42 on Wednesday. The company has a market capitalization of $1.95 billion, a P/E ratio of -6.35, a PEG ratio of 0.24 and a beta of 0.23. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics has a 12 month low of $14.68 and a 12 month high of $25.32. The firm has a fifty day simple moving average of $17.03 and a 200-day simple moving average of $18.40.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in SRPT. Yousif Capital Management LLC lifted its position in Sarepta Therapeutics by 1.9% during the fourth quarter. Yousif Capital Management LLC now owns 25,704 shares of the biotechnology company’s stock valued at $541,000 after purchasing an additional 481 shares during the period. PNC Financial Services Group Inc. grew its position in Sarepta Therapeutics by 7.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company’s stock worth $190,000 after purchasing an additional 636 shares during the period. Thrivent Financial for Lutherans grew its position in Sarepta Therapeutics by 3.3% during the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 744 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Sarepta Therapeutics by 1.8% during the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company’s stock valued at $829,000 after buying an additional 758 shares during the last quarter. Finally, Larson Financial Group LLC raised its stake in shares of Sarepta Therapeutics by 82.5% during the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 851 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.